坦度螺酮联合奥氮平对精神分裂症患者认知功能的影响被引量：2

下载PDF

导出

摘要目的探讨坦度螺酮联合奥氮平对精神分裂症患者认知功能的改善作用。方法将精神分裂症患者随机分为奥氮平治疗组(37例)和坦度螺酮联合奥氮平治疗组(38例),在治疗前及治疗12周末应用标准化的精神分裂症认知功能成套测验(MCCB)评定认知功能,应用阳性与阴性症状量表(PANSS)评定疗效。结果治疗12周末两组间比较,坦度螺酮联合奥氮平组在连线、持续操作、数字序列、空间广度、迷宫分项目测验成绩上优于奥氮平组,差异具有统计学意义(均P<0.05);在PANSS总分、阳性症状分、阴性症状分及一般精神病理分上两组间差异无统计学意义(均P>0.05)。结论坦度螺酮联合奥氮平治疗能有效改善精神分裂症患者的认知功能,但不能提高精神分裂症患者的疗效。

作者宋光明李建华关铁峰

机构地区湖州市第三人民医院

出处《浙江实用医学》 2015年第1期34-35,44,共3页 Zhejiang Practical Medicine

关键词精神分裂症坦度螺酮奥氮平认知功能

分类号 R749.3 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献7

1Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implica- tions for MATRICS. Schizophrenia Research,2004, 72( 1 ) :41.
2Batch DM, Gold JM, Goldberg TE,et al. ldentificalion of separable cognitive factors in schizophrenia. Schizophrenia Research ,2004, 72(2):29.
3Sumiyoshi T,Serotonia I. Receptors in the Pathophysiology of Schizophrenia: Development of Novel Cognition Enhncing Therpeutics. Adv Ther, 2008,25(10) :1037.
4Eriksson TM, Elvander-tottie E, D'Addario C, et al. The role of 5-HT1A reeeptors in learning and memory. Behav- ioral Brain Research, 2008,31 ( 1 ) :54.
5Smniyoshi T, Matsui M, Yamashita 1. The effect of tan- dospironc, a serotonin (1A) agonist, on memory function in schizophrenia. Biol Psychiatry, 2001, 49(10):861.
6Uehara T, Matsuoka T, Sumiyoshi T. Tandospimne, a 5- HT1A partial agonist, ameliorates aberrant lactate production in the prefrontal cortex of rats exposed to blockade of N- methy-D-aspartate receptors; Toward the therapeutics of cog- nitive impairment of schizophrenia.Front Behav Neurosci, 2014,8(3) :291.
7邹军辉,卢卫红,王红尔,岑利平,易正辉,龙彬.坦度螺酮对首发精神分裂症患者认知功能的影响[J].中国医药导报,2012,9(28):85-86. 被引量：8

二级参考文献7

1Edward K,Shaloo G,Susan B,et al. Adherence and outcomes associated with copayment burden in schizophrenia:a cross-sectional survey [J]. J Med Econ,2010,13(2) : 185-192.
2Sumiyoshi T,Park S,Jayathilake K,et al. Effect of buspirone,a sero- toninlA partial agonist,on cognitive function inschizophrenia:a ran- domized,double-blind,placebo-controlled study [J]. Schizophr Res,2007,95 (1-3) : 158-168.
3Yasuno T,Suhara T,Ichimiya T,et al. Inhibitory effect of hippocampal 5-HT1A receptors on human explicitmemory [J]. Am J Psychiatry,2003,160 (3) :334-340.
4Sumiyoshi T. Semtonia receptors in the pathophysiology of schizophreni- a:development of novel cognition enhancing therpeutics [J]. Adv Ther, 2008,25 (10) : 1037-1056.
5Sumiyoshi T,Matsui M. Enhancement of cognitive performance in schizophrenia by addition of tandospimne to neuroleptic treatment [J]. Am J Psychiatry ,2001,158 : 1722-1725.
6Sumiyoshi T, Matsui M ,Yamashita I. The effect of tandospimne, B sero- tonin( 1A)agonist,on memory function in schizophrenia [J]. Biol Psychi- atry,2001,49(10) :861-865.
7Sumiyoshi T,Higuehi Y,Matsui M,et al. Effective adjunctive use of tandospimne with perospimne for enhancing verbalmemory and quality 3f life schizophrenia [J]. Prog Neuro Psychopharmacol Biol Psychiatry, 2001,31:965-967.